Our Mission

Our mission is to unite biopharma, physicians, and patients to transform the standard of care and improve outcomes with personalized diagnostics.

Our Vision

We envision a world where all critical diseases are diagnosed early and treated quickly with the guidance of personalized diagnostic solutions, so humanity can thrive without the burden of disease.


We Are Inclusive

Our culture is built on respect, transparency, trust, integrity, and individual accountability, creating a diverse community where everyone can prosper.


We Are Nimble

We quickly adapt to anticipate healthcare needs by providing scientifically-driven, innovative solutions.

Making an Impact

We Are Confident

We tackle important clinical questions to improve people’s lives.


We Get Results

We set expectations high. Our empowered, motivated, and competitive teams work together to boldly overcome barriers.

Diagnostic solutions helping to answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.

History of Biodesix

biodesix logo

2006 The Origin of Biodesix

Biodesix was founded in 2006 in Boulder, Colorado by David Brunel, Rob Cawthorn, and Heinrich Roder, PhD. David Brunel, previously the co-founder and President of SomaLogic, was named the new President and CEO of Biodesix.

The name Biodesix started with the word biodesics, which is analogous to “Geodesics”, a term, describing the shortest path between two points on the Earth’s surface. From the very beginning, the company aspired to accelerate and streamline diagnostic processes in complex disease states.

2007 The Biodesix Early Mission: To Become the Leader in Proteomics

The initial Biodesix mission was to become the leading provider of proteomic mass spectrometry-based clinical diagnostics. At that time, Biodesix was developing diagnostic tools for early and minimally-invasive detection of pan-cancer, with the goal of stratifying patient populations to personalized treatment protocols.

veristrat logo

2009 Biodesix Advances the Field of Personalized Medicine with the Launch of the VeriStrat® Proteomic Test

ny state logo

2011 New York State CLEP Approval

Biodesix received their first clinical laboratory evaluation program certification for the VeriStrat® Proteomic Test from the New York State Department of Health’s Wadsworth Center.

2013 Biodesix Business Development Team Partners with GlobeImmune to Develop the First Immunotherapy Classifier

Biodesix announces a collaborative agreement with Bruker Daltonics to support Biodesix’ VeriStrat diagnostic test as well as future diagnostic tests based on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.

2014 Biodesix Shifts Focus to Lung Cancer

Biodesix announces the first prospective biomarker-stratified validation study in LANCET ONCOLOGY. The study highlights how VeriStrat® can robustly predict differential treatment outcomes for Non-Small Cell Lung Cancer (NSCLC).

aveo oncology logo

2014 Biodesix Business Development Group Announces Partnership with AVEO Oncology

Aveo and Biodesix announce an exploratory project, presented at ESMO 2014 Congress – a Phase 2 clinical study focused on VeriStrat-selected patients with NSCLC. As a result, AVEO and Biodesix partner to co-develop and commercialize Ficlatuzamab with a companion diagnostic for treatment of NSCLC.

biodesix logo

2014 In a Move to Highlight Personalized Medicine, Biodesix Updates the Company Logo

The new Biodesix logo is unveiled, which is reminiscent of a fingerprint. The new logo speaks to the personalized medicine approach, using the guidance of diagnostic tests developed by Biodesix.

bio rad and genestrat logos

2015 Biodesix Announces Partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb)

Biodesix and Bio-Rad join together to develop the GeneStrat ddPCR™ genomic panel for patients with NSCLC.

biodesix lung logo

2016 Biodesix Takes a Novel Multi-Omic Approach to Diagnostic Testing

Physicians are now able to easily order both GeneStrat® and VeriStrat® for their patients, in order to receive valuable genomic and proteomic insights from just one simple blood draw. The combination of the tests equips physicians with comprehensive biological information about the nature of the patient’s tumor and the health of the immune system, in order to better understand cancer aggressiveness and treatment options.

2016 Biodesix’s 2nd New York State CLEP Approval

Biodesix receives their second Clinical Laboratory Evaluation Program approval with certification for the GeneStrat® ddPCR Test from the New York State Department of Health’s Wadsworth Center.

journal of molecular diagnostics logo

2017 The First Peer-Reviewed Publication on the GeneStrat® ddPCR Genomic Test is Published in the Journal of Molecular Diagnostics

2017 Biodesix and ProGenetics enter into an International Agreement

Biodesix commercial blood-based lung diagnostic tests become available for clinical use in Israel for the first time.

Biodesix nodify lung illustration

2018-2019 Biodesix Spans the Lung Cancer Continuum of Care with Acquisitions of Integrated Diagnostics and Oncimmune, USA

Biodesix acquires Integrated Diagnostics (Seattle, Washington) and the technology behind what is known today as the Nodify XL2® Test. Shortly after, Biodesix acquires Oncimmune USA (De Soto, Kansas) and the technology that is behind the Nodify CDT® Test.

Together, these two blood-based proteomic tests (the Nodify CDT® & Nodify XL2® tests) help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.

2018 In a Joint Effort with Genentech, Researchers from Biodesix Present Findings on a Test Designed to Predict Response to Atezolizumab (Tecentriq®) in Patients with NSCLC

2020 A Year of Change and Growth for Biodesix

CEO Scott Hutton

2020 Biodesix Announces Scott Hutton as CEO

2020 Biodesix Announces Initiation of Clinical Phase Biomarker Development Program with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.

MARCH 2020 Biodesix Steps Up to Fight the COVID-19 Pandemic

In partnership with Bio-Rad, Biodesix introduces highly sensitive, rapid turn-around droplet digital PCR (ddPCR) technology to detect the SARS CoV-2, the virus that causes COVID-19, in patient samples. In addition, Biodesix launches the WorkSafe Employer Testing Program which is an end-to-end customized solution to assist in preventing and slowing the spread of COVID-19 while resuming business operations.

Sign on building celebrating BDSX becoming Nasdaq listed

OCTOBER 2020 Biodesix Announces Initial Public Offering Under the BDSX Ticker Symbol

The stated and communicated goal as part of that public fund-raising effort was to “answer every clinical question across the continuum of care in NSCLC while expanding into lung disease.”

2021 Biodesix and HiberCell Initiate Broad Collaboration for Companion Diagnostic Discovery, Development and Commercialization

iqlung logo

2022 Biodesix Launches the GeneStrat NGS™ test and IQ Lung™ Treatment Guidance Testing

IQLung testing consists of the GeneStrat® targeted test, the GeneStrat NGS™ genomic test, with unprecedented turnaround time for results and the VeriStrat® proteomic test for a broader view of each patient's disease state with results in 3 business days.*


Unyielding Commitment to Patients

Each patient should have insights as unique as they are to ensure they receive the best care possible.


Expertise You Can Believe In

Our transparent and resolute approach delivers personalized diagnostic insights to help physicians advance patient care in some of the most challenging disease states.



Merging Technical and Clinical Acumen

A unique and innovative approach is critical to finding diagnostic solutions to your questions. We leverage transparent AI with our proven multi-omic approach to build informative diagnostic solutions.



Leveraging Multiple Technologies and Proprietary AI

We employ innovative and proprietary approaches to discover, develop, and commercialize diagnostic tests to help answer critical clinical and research questions.

*3 business days represents the average turnaround time for testing, individual test turnaround times may vary.